Bodhi Tree Biotechnology Inc Financials
Bodhi Tree Biotechnology Inc (BDTB) reported $17K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
BDTB currently operates more like a cash-funded corporate shell than a self-supporting business, with overhead overwhelming activity.
With$109K of cash and$0 liabilities, financial pressure is not coming from leverage or creditor claims on the balance sheet. Reported revenue of$17K sits far below the operating cash outflow of-$150K , which shows the entity is currently using stored cash to support its existence rather than turning operations into cash.
Selling, general and administrative expense of
Operating cash outflow of
Financial Health Signals
Bodhi Tree Biotechnology Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Bodhi Tree Biotechnology Inc reported a net loss of $150K while operations used $150K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Bodhi Tree Biotechnology Inc reported an operating loss of $148K against $2 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Bodhi Tree Biotechnology Inc generated $17K in revenue in fiscal year 2025.
Bodhi Tree Biotechnology Inc reported -$150K in net income in fiscal year 2025.
Bodhi Tree Biotechnology Inc earned -$0.01 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Bodhi Tree Biotechnology Inc held $109K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Bodhi Tree Biotechnology Inc's ROE was -125.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
BDTB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 |
|---|---|---|
| Revenue | N/A | $17K |
| SG&A Expenses | N/A | $165K |
| Operating Income | N/A | -$148K |
| Interest Expense | N/A | $2 |
| Income Tax | N/A | $2K |
| Net Income | N/A | -$150K |
| EPS (Diluted) | — | -$0.01 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BDTB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 |
|---|---|
| Total Assets | $119K |
| Cash & Equivalents | $109K |
| Total Liabilities | $0 |
| Total Equity | $119K |
| Retained Earnings | -$212K |
Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Goodwill, Current Liabilities, Long-Term Debt.
BDTB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 |
|---|---|---|
| Operating Cash Flow | -$116K | -$150K |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BDTB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 |
|---|---|
| Operating Margin | -868.3% |
| Net Margin | -880.4% |
| Return on Equity | -125.6% |
| Return on Assets | -125.6% |
| Debt-to-Equity | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, Current Ratio, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Where Bodhi Tree Biotechnology Inc Ranks
Frequently Asked Questions
What is Bodhi Tree Biotechnology Inc's annual revenue?
Bodhi Tree Biotechnology Inc (BDTB) reported $17K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Bodhi Tree Biotechnology Inc profitable?
No, Bodhi Tree Biotechnology Inc (BDTB) reported a net income of -$150K in fiscal year 2025.
What is Bodhi Tree Biotechnology Inc's return on equity (ROE)?
Bodhi Tree Biotechnology Inc (BDTB) has a return on equity of -125.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bodhi Tree Biotechnology Inc's operating cash flow?
Bodhi Tree Biotechnology Inc (BDTB) recorded an outflow of $150K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bodhi Tree Biotechnology Inc's total assets?
Bodhi Tree Biotechnology Inc (BDTB) had $119K in total assets as of fiscal year 2025, including both current and long-term assets.
What is Bodhi Tree Biotechnology Inc's debt-to-equity ratio?
Bodhi Tree Biotechnology Inc (BDTB) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bodhi Tree Biotechnology Inc's return on assets (ROA)?
Bodhi Tree Biotechnology Inc (BDTB) had a return on assets of -125.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bodhi Tree Biotechnology Inc's cash runway?
Based on fiscal year 2025 data, Bodhi Tree Biotechnology Inc (BDTB) had $109K in cash against an annual operating cash burn of $150K. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Are Bodhi Tree Biotechnology Inc's earnings high quality?
Bodhi Tree Biotechnology Inc (BDTB) reported a net loss of $150K while operations used $150K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bodhi Tree Biotechnology Inc cover its interest payments?
Bodhi Tree Biotechnology Inc (BDTB) reported an operating loss of $148K against $2 in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.